Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector...al population-based interventions to reduce CVD risk factors in the entire population.
Methods: We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs.
Results: A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of
individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability ofaffordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). Thisalso emphasises the need to re-orient health systems in LMICs towards chronic diseases management.
Conclusion: The large burden of CVD in LMICs and the fact that persons with high
CVD can be identified and managed along cost-effective interventions mean that
health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level.
more
This clinical job aid addresses the importance of maternal health and antiretroviral therapy adherence, as well as care and testing for the HIV-exposed infant until the infant’s final HIV diagnosis after the end of breastfeeding.
Regulation of the Minister of Health of the Republic of Indonesia Number 74 Year 2014: Guidelines for Implementation of Hiv Counseling and Test
This guidance provides an overview of interventions to improve early diagnosis of TB and treatment completion in these populations, as well as factors to consider when developing programmes for health communication, awareness and education, and programme monitoring and evaluation
The overall objective of this implementation plan is to define the strategy for implementation of the Xpert MTB/RIF test for rapid detection of TB and rifampicin (RIF) resistance in Tanzania, within the context of the National Tuberculosis and Leprosy Programme (NTLP) strategic plan and other nation...al health guidelines. It is intended to serve as the main guiding document for national, regional and local programme managers, clinicians, coordinators, laboratory staff and other health workers; national and regional reference laboratories; local and international implementing partners; and donors involved in TB control.
more
Revised National TB Control Programme. Annual Status Report
The purpose of the Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care is to provide professionals with practical recommendations based on scientific evidence to assist in the detection and effective treatment of these disorders
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PLOS Medicine | DOI:10.1371/journal.pmed.1002088 August 23, 2016
NICE Scientific Advice is providing free fast track advice for researchers who are developing novel diagnostics or therapeutics for COVID-19. The team is working to help researchers from around the world optimise their approach to generating the essential evidence required for health technology ass...essments, which inform decision making.
more
To get the latest information about the drugs, lab tests, that are related to Covid-19 at no charge please check below Links from our Drug referential database Lexicomp
Video of how to obtain a good SARS CoV II sample
New England Journal of Medicne NJM 2020 382, 22
You can download the video here https://medbox.org/document/how-to-obtain-a-nasopharyngeal-swab-specimen-video#GO